Pirtobrutinib in relapsed or refractory mantle cell lymphoma: a profile of its use

online resource

posted on 2024-01-22, 20:39 authored by Young-A Heo

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest Young-A Heo, a salaried employee of Adis International Ltd/Springer Nature and an editor of Drugs & Therapy Perspectives, was not involved in any publishing decisions for the manuscript and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable

Additional information about this Adis Drug Review can be found here

Abstract

Pirtobrutinib (Jaypirca^®), an oral, small molecule, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, is a promising new treatment option for patients with relapsed or refractory mantle cell lymphoma (MCL), including those who had received a covalent BTK inhibitor. In a multicentre, open-label, phase 1/2 BRUIN trial, pirtobrutinib demonstrated meaningful response rates and durable efficacy in patients with heavily pretreated (including a covalent BTK inhibitor) relapsed or refractory MCL. Pirtobrutinib had a manageable tolerability profile, with most treatment related adverse events being mild to moderate in severity. Longer term, the tolerability profile of pirtobrutinib revealed no new safety signals.